1. Home
  2. ESTC vs COGT Comparison

ESTC vs COGT Comparison

Compare ESTC & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elastic N.V.

ESTC

Elastic N.V.

HOLD

Current Price

$89.29

Market Cap

6.5B

Sector

Technology

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$31.98

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESTC
COGT
Founded
2012
2014
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.1B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
ESTC
COGT
Price
$89.29
$31.98
Analyst Decision
Buy
Strong Buy
Analyst Count
28
15
Target Price
$91.38
$36.21
AVG Volume (30 Days)
2.8M
1.5M
Earning Date
05-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
429.81
N/A
EPS
N/A
N/A
Revenue
$1,739,331,000.00
$7,871,000.00
Revenue This Year
$19.06
N/A
Revenue Next Year
$13.42
$1,733.58
P/E Ratio
N/A
N/A
Revenue Growth
17.26
N/A
52 Week Low
$42.05
$12.44
52 Week High
$108.00
$43.73

Technical Indicators

Market Signals
Indicator
ESTC
COGT
Relative Strength Index (RSI) 56.87 34.08
Support Level $80.47 $30.90
Resistance Level $108.00 $37.69
Average True Range (ATR) 3.67 1.25
MACD -0.86 -0.16
Stochastic Oscillator 47.52 14.45

Price Performance

Historical Comparison
ESTC
COGT

About ESTC Elastic N.V.

Elastic is a software company that specializes in AI-search, observability, and security deployments. Its search division offers both traditional keyword search and vector search methods to enable more context-aware querying. The software has open-source origins but generates revenue through valuable add-ons, including simplified data orchestration and server scaling techniques.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: